Scilex Holding (SCLX) Gains from Investment Securities (2020 - 2026)
Scilex Holding (SCLX) recorded quarterly Gains from Investment Securities of $10000.0 in Q1 2026, down 99.95% quarter-over-quarter from $19.2 million in Q4 2025.
Scilex Holding (SCLX) Gains from Investment Securities (2020 - 2026) Analysis & Trends
Scilex Holding's Gains from Investment Securities history runs 7 years deep, the most recent figure standing at $10000.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities changed N/A year-over-year to $10000.0; the TTM figure through Mar 2026 stood at $10000.0 (up 119.61% YoY), while the FY2025 annual figure was $1.5 million, up 146203.5% from the prior year.
- Gains from Investment Securities was $10000.0 for Q1 2026 at Scilex Holding, down from $19.2 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $19.2 million in Q4 2025 to a low of -$2.5 million in Q2 2022.
- Historically, Gains from Investment Securities has averaged $1.1 million across 5 years, with a median of $24500.0 in 2024.
- The sharpest annual moves came in 2022 and 2025: Gains from Investment Securities sank 3800.0% in 2022, then jumped 64160.0% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $685000.0 in 2022, then slumped by 107.45% to -$51000.0 in 2023, then jumped by 41.18% to -$30000.0 in 2024, then surged by 64160.0% to $19.2 million in 2025, then sank by 99.95% to $10000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $10000.0 (Q1 2026), $19.2 million (Q4 2025), and $30000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn |
| 10 | Scilex Holding | 48.31 Mn | -101.62 Mn | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10,000.00 |
| Mar 31, 2026 | 10,000.00 |
| Dec 31, 2025 | 19.22 Mn |
| Dec 31, 2025 | 19.22 Mn |
| Sep 30, 2025 | 30,000.00 |
| Sep 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Dec 31, 2024 | -30,000.00 |
| Dec 31, 2024 | -30,000.00 |
| Sep 30, 2024 | 476,000.00 |
| Sep 30, 2024 | 476,000.00 |
| Jun 30, 2024 | 121,000.00 |
| Jun 30, 2024 | 121,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | -51,000.00 |
| Dec 31, 2023 | -51,000.00 |
| Sep 30, 2023 | 14,820.00 |
| Sep 30, 2023 | 14,820.00 |